Allogene Therapeutics, Inc. (ALLO) Financial Statements
Allogene Therapeutics, Inc. (ALLO) reported trailing twelve-month revenue of $4.6M (up 223.2% year on year) and net income of -$165.5M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: -$115.5M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
ALLOAllogene Therapeutics, Inc.Follow ALLO — free
—
Price chart with a free account
- Market cap
- 431.9M
- P/E TTM
- —
- Dividend yield
- 0.0%
- 52-week
- —
- Next earnings
- 29 Oct, in 5 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|
| Revenue | 0.11 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Gross profit | — | — | — | — | -0.00 | — | |
| Research & development | 0.22 | 0.26 | 0.24 | 0.19 | 0.15 | 0.12 | |
| Operating income | -0.18 | -0.34 | -0.33 | -0.27 | -0.21 | -0.18 | |
| Pre-tax income | -0.18 | -0.34 | -0.33 | -0.26 | -0.19 | — | |
| Income tax | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | |
| Net income | -0.18 | -0.34 | -0.33 | -0.26 | -0.19 | -0.17 | |
| Diluted EPS ($) | -1.34 | -2.38 | -2.09 | -1.32 | -0.87 | -0.51 | |
| Diluted shares (bn) | 0.136 | 0.143 | 0.157 | 0.195 | 0.221 | — |
USD billions · SEC XBRL
Allogene Therapeutics, Inc. — questions
- What is Allogene Therapeutics, Inc.'s revenue?
- $4.6M over the twelve months to 2026-06-30, up 223.2% year on year, from its 10-Q and 10-K filings.
- What is Allogene Therapeutics, Inc.'s net income?
- -$165.5M over the twelve months to 2026-06-30.
- What is Allogene Therapeutics, Inc.'s free cash flow?
- -$115.5M over the twelve months to 2026-06-30.
- What are Allogene Therapeutics, Inc.'s diluted earnings per share?
- $-0.51 over the twelve months to 2026-06-30.
Every figure on this page comes from Allogene Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.